248 related articles for article (PubMed ID: 27267855)
1. CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy.
Zhao S; Chen C; Chang K; Karnad A; Jagirdar J; Kumar AP; Freeman JW
Clin Cancer Res; 2016 Nov; 22(22):5592-5604. PubMed ID: 27267855
[TBL] [Abstract][Full Text] [Related]
2. GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer.
Chen C; Wu B; Wang M; Chen J; Huang Z; Shi JS
PeerJ; 2022; 10():e12728. PubMed ID: 35846884
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching.
Chen C; Zhao S; Zhao X; Cao L; Karnad A; Kumar AP; Freeman JW
Cell Death Dis; 2022 Aug; 13(8):682. PubMed ID: 35931675
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.
Molejon MI; Tellechea JI; Loncle C; Gayet O; Gilabert M; Duconseil P; Lopez-Millan MB; Moutardier V; Gasmi M; Garcia S; Turrini O; Ouaissi M; Poizat F; Dusetti N; Iovanna J
Oncotarget; 2015 Apr; 6(10):7408-23. PubMed ID: 25797268
[TBL] [Abstract][Full Text] [Related]
5. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
Hong SP; Wen J; Bang S; Park S; Song SY
Int J Cancer; 2009 Nov; 125(10):2323-31. PubMed ID: 19598259
[TBL] [Abstract][Full Text] [Related]
6. The CD44 standard isoform contributes to radioresistance of pancreatic cancer cells.
Tsubouchi K; Minami K; Hayashi N; Yokoyama Y; Mori S; Yamamoto H; Koizumi M
J Radiat Res; 2017 Nov; 58(6):816-826. PubMed ID: 29106581
[TBL] [Abstract][Full Text] [Related]
7. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
[TBL] [Abstract][Full Text] [Related]
8. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
9. Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells.
Kumar S; Inigo JR; Kumar R; Chaudhary AK; O'Malley J; Balachandar S; Wang J; Attwood K; Yadav N; Hochwald S; Wang X; Chandra D
Cancer Lett; 2018 Jan; 413():82-93. PubMed ID: 29107110
[TBL] [Abstract][Full Text] [Related]
10. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer.
Zhang Y; Wei J; Wang H; Xue X; An Y; Tang D; Yuan Z; Wang F; Wu J; Zhang J; Miao Y
Oncol Rep; 2012 May; 27(5):1599-605. PubMed ID: 22322379
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
12. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
[TBL] [Abstract][Full Text] [Related]
13. TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44.
Chen Q; Gu M; Cai ZK; Zhao H; Sun SC; Liu C; Zhan M; Chen YB; Wang Z
Cell Mol Life Sci; 2021 Feb; 78(3):949-962. PubMed ID: 32440711
[TBL] [Abstract][Full Text] [Related]
14. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
16. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
17. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E
Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962
[TBL] [Abstract][Full Text] [Related]
19. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
20. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP
Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]